Supplementary table I- Efficacy and tolerance of dupilumab in obese patients with moderate-to-severe atopic dermatitis. Dupuis et al
Published: 18 December 2023| Version 1 | DOI: 10.17632/d23bwhdnkh.1
Supplementary Table I: Adverse events during the follow-up period in patients treated with dupilumab.
Universite de Lille